Ketoprofen

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Ketoprofen

Examples of brand names: Orudis [DE]

ATC code: M01AE03

Main use (for orientation): Pain; inflammation

Documented research summary

No reliable finding for the pair. Chemically conjugated CBD–ketoprofen compounds are new molecules, not usual co-administration.

Uncertainties and limitations

Corrected to a human single-ingredient ketoprofen product, oral capsule (Oncora). Not the veterinary Draxxin combination.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Insufficient pair-specific data

Mechanism / drug context: Ketoprofen: glucuronidation, reversible acyl glucuronide, renal relevance.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [V2_LABEL_D0171_Human]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: KETOPROFEN capsules (Oncora Pharma), oral human monotherapy [V2_LABEL_D0171_Human]

Source role [A6_P_40609153]: Scope distinction / context

Statement supported: Ketoprofen as a separate positive control.

Source: Cannabidiol interactions with Δ-9-tetrahydrocannabinol on antinociception after carrageenan-induced inflammatory pain in male and female rats. [A6_P_40609153]

Source role [C_PR_37513798]: Scope distinction / context

Statement supported: Chemically linked CBD–NSAID molecules rather than co-administration of unchanged active ingredients.

Source: Novel Molecular Consortia of Cannabidiol with Nonsteroidal Anti-Inflammatory Drugs Inhibit Emerging Coronaviruses' Entry. [C_PR_37513798]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[V2_LABEL_D0171_Human] KETOPROFEN capsules (Oncora Pharma), oral human monotherapy

Original source / bibliographic reference

Authors: Oncora Pharma, LLC

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[A6_P_40609153] Cannabidiol interactions with Δ-9-tetrahydrocannabinol on antinociception after carrageenan-induced inflammatory pain in male and female rats.

Original source / bibliographic reference

Authors: Jenkins BW, Moore CF, Weerts EM.

Year: 2025

Source type: Original publication; abstract screened

DOI: 10.1016/j.jpet.2025.103625

PMID: 40609153

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[C_PR_37513798] Novel Molecular Consortia of Cannabidiol with Nonsteroidal Anti-Inflammatory Drugs Inhibit Emerging Coronaviruses' Entry.

Original source / bibliographic reference

Authors: Pawełczyk A, Nowak R, Gazecka M, Jelińska A, Zaprutko L, Zmora P.

Year: 2023

Source type: Primary source, abstract read

DOI: 10.3390/pathogens12070951

PMID: 37513798

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility